Natera Inc

6 de nov. de 2026, 21:03 UTC

Natera, Inc. shares fell sharply after reporting Q3 revenue of $794 million but a wider loss of $0.42 per share, contributing to investor uncertainty.

5 de nov. de 2026, 23:03 UTC

Natera, Inc. appointed Solomon Moshkevich as CEO and reported a Q3 net loss of $59.9 million, missing analyst expectations for a $0.28 loss per share.

4 de nov. de 2026, 21:03 UTC

Natera, Inc. announced three peer-reviewed publications demonstrating the effectiveness of its Signatera test in managing head and neck squamous cell carcinoma (HNSCC).

3 de nov. de 2026, 21:07 UTC

Natera's Signatera test receives Medicare coverage for hepatocellular carcinoma, supported by a study showing 83% sensitivity and 100% specificity.

2 de nov. de 2026, 23:02 UTC

Natera, Inc. is declining in after-market hours, continuing a trend of lower performance over the past three sessions amid ongoing weakness in the biotechnology sector.

30 de out. de 2026, 20:04 UTC

ARK Genomic Revolution ETF fell sharply, contributing to negative sentiment, while Natera, Inc. also declined, diverging from a recent trend amid high market volume.

29 de out. de 2026, 23:41 UTC

Natera, Inc. shares are lower in after-market trading, tracking a decline in the ARK Genomic Revolution ETF amid mixed earnings reports in biotechnology.

28 de out. de 2026, 20:02 UTC

Natera, Inc. shares are advancing during Wednesday's session with unusually high market volume, ahead of its earnings announcement in eight days.

26 de out. de 2026, 19:56 UTC

Natera Inc presented findings at the American Society of Nephrology, revealing a median 5.3-year delay in chronic kidney disease diagnosis and care access issues.

23 de out. de 2026, 20:07 UTC

Roth initiates coverage on Natera Inc with a Buy rating and sets a price target of $475, reflecting confidence in the company's growth potential.

22 de out. de 2026, 20:03 UTC

Natera Inc shares are declining, having significantly pulled back from earlier gains and reaching a notable low around midday, amid unusually high market volume.

20 de out. de 2026, 19:36 UTC

Natera Inc is trading higher, rebounding from an earlier dip to reach a mid-afternoon peak, currently above its 20-day moving average.

19 de out. de 2026, 22:51 UTC

Natera Inc shares traded modestly lower during after-market hours on Monday, remaining below their 20-day moving average amid broader market weakness.

17 de out. de 2026, 00:01 UTC

Natera Inc shares are trading modestly lower in after-market hours, remaining below their 20-day moving average amid broader market weakness.

16 de out. de 2026, 23:06 UTC

Natera Inc is trading slightly higher in after-market hours, fluctuating between nearly 1.71% below and 0.31% above Friday's close.

15 de out. de 2026, 20:07 UTC

Natera's Signatera test recognized in TIME's Best Inventions of 2026, underscoring its impact on cancer care and supported by over 200 peer-reviewed publications.

14 de out. de 2026, 22:21 UTC

Natera Inc shares are trading modestly lower in after-market hours, following a significant decline in major indices amid rising investor anxiety over interest rate decisions.

13 de out. de 2026, 20:08 UTC

Natera Inc. partners with TransCode Therapeutics to boost patient enrollment in a colorectal cancer trial, while TD Cowen and Morgan Stanley raise price targets to $480 and $435.

12 de out. de 2026, 20:06 UTC

Natera Inc shares are declining, pulling back from an earlier high, despite being nominated for the 2026 Future Investors Awards as a top healthcare company.

9 de out. de 2026, 20:07 UTC

Natera Inc.'s multi-cancer early detection assay received Breakthrough Device designation from the FDA, aimed at improving early cancer diagnosis and treatment options.

8 de out. de 2026, 20:07 UTC

Baird analyst Catherine Ramsey Schulte raised Natera Inc's price target to $458.00 from $376.00 while maintaining an Outperform rating.

7 de out. de 2026, 20:00 UTC

Natera Inc. shares fell despite the enrollment of patients in a study for advanced melanoma and Barclays raising its price target to $475 from $340.

6 de out. de 2026, 20:00 UTC

Natera Inc shares fell amid broader biotechnology sector weakness, despite positive data on its Signatera product and Citigroup raising its price target to $480.

5 de out. de 2026, 23:05 UTC

Citi raised its price target on Natera Inc to $480 from $365, maintaining a Buy rating amid growth in its Signatera product and health segments.

2 de out. de 2026, 20:07 UTC

Natera Inc shares are higher amid a broadly advancing market, reflecting positive momentum as labor statistics influence expectations for future interest rates.

1 de out. de 2026, 20:07 UTC

Natera Inc shares are declining, reversing earlier gains despite remaining above the 20-day moving average and near the upper end of the one-month range.

30 de set. de 2026, 23:00 UTC

Natera Inc declined in after-market trading, settling below Wednesday's close after retreating from an early high, despite remaining higher over the past month.

29 de set. de 2026, 19:15 UTC

Natera Inc shares are modestly higher as social media buzz highlights positive cash flows and a potential cancer screening test amid market volatility.

28 de set. de 2026, 20:07 UTC

Natera's shares fell amid a broader market decline, despite RBC Capital raising its price target to $460 and maintaining an Outperform rating.

25 de set. de 2026, 19:46 UTC

RBC Capital raised its price target on Natera Inc to $460, maintaining an Outperform rating, as shares trade modestly higher amid strong market position.